ARTV · Artiva Biotherapeutics, Inc.
← all insidersBiological Products, (No Diagnostic Substances) · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades22
Distinct insiders5
Bought$10.03M
Sold$1.02M
Net flow$9.01M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | Stoppel Laura | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | Sorg Elaine K. | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | HOUGEN ELIZABETH L | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | DANIELS BRIAN | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | Baker Daniel G. | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-08 | MOORE ALISON | Director | A | ▲ buy | 13,750→ 13,750 Common Stock | — | — | 13,750 | — | — | filing |
| 2026-09-04 | Horan Christopher | Officer (Chief Tech Operations Officer) | S | ▼ sell | 10,3660 | $11.16 | $115.6K | 283,084 | −4% | −0.02% (now 0.58%) | filing |
| 2026-09-04 | Bush Jennifer | Officer (COO, CLO, Compliance Officer) | S | ▼ sell | 8,3910 | $11.16 | $93.6K | 329,529 | −2% | −0.02% (now 0.67%) | filing |
| 2026-09-04 | Banerjee Subhashis | Officer (Chief Medical Officer) | S | ▼ sell | 1,1000 | $11.16 | $12.3K | 140,947 | −0.8% | −<0.01% (now 0.29%) | filing |
| 2026-09-04 | Aslan Fred | Director, Officer (Chief Executive Officer) | S | ▼ sell | 61,8880 | $11.16 | $690.4K | 1,473,194 | −4% | −0.13% (now 3.0%) | filing |
| 2026-08-31 | Banerjee Subhashis | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 5,306→ 5,306 Common Stock | — | — | 74,265 | — | — | filing |
| 2026-08-31 | Banerjee Subhashis | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 8,2220 | $12.01 | $98.7K | 142,047 | −5% | −0.02% (now 0.29%) | filing |
| 2026-08-31 | Banerjee Subhashis | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 5,3060 | $1.92 | $10.2K | 150,269 | +4% | +0.01% (now 0.31%) | filing |
| 2026-08-19 | Banerjee Subhashis | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 429→ 429 Common Stock | — | — | 79,571 | — | — | filing |
| 2026-08-19 | Banerjee Subhashis | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 4290 | $12.00 | $5.1K | 144,963 | −0.3% | −<0.01% (now 0.30%) | filing |
| 2026-08-19 | Banerjee Subhashis | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 4290 | $1.92 | $824 | 145,392 | +0.3% | +<0.01% (now 0.30%) | filing |
| 2026-07-31 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 24,9440 | $9.93 | $247.7K | 17,329,570 | +0.1% | +0.05% (now 35%) | filing |
| 2026-07-31 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 20,8240 | $9.99 | $208.0K | 17,304,626 | +0.1% | +0.04% (now 35%) | filing |
| 2026-07-28 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 41,3190 | $9.99 | $412.8K | 17,283,802 | +0.2% | +0.08% (now 35%) | filing |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 59,8800 | $9.96 | $596.4K | 17,242,483 | +0.3% | +0.12% (now 35%) | filing |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 84,1240 | $9.93 | $835.4K | 17,182,603 | +0.5% | +0.17% (now 35%) | filing |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 120,5820 | $9.55 | $1.15M | 17,098,479 | +0.7% | +0.25% (now 35%) | filing |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 6,5220 | $8.94 | $58.3K | 16,817,543 | +<0.1% | +0.01% (now 34%) | filing |
| 2026-07-20 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 7,8820 | $8.95 | $70.5K | 16,977,927 | +<0.1% | +0.02% (now 35%) | filing |
| 2026-07-20 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 152,4720 | $8.93 | $1.36M | 16,970,045 | +0.9% | +0.31% (now 35%) | filing |
| 2026-07-14 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 6,5520 | $8.94 | $58.6K | 16,817,573 | +<0.1% | +0.01% (now 34%) | filing |
| 2026-07-14 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 15,1020 | $8.97 | $135.5K | 16,811,021 | +<0.1% | +0.03% (now 34%) | filing |
| 2026-06-29 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 1,8760 | $8.98 | $16.8K | 16,795,919 | +<0.1% | +<0.01% (now 34%) | filing |
| 2026-06-29 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 31,0000 | $8.88 | $275.3K | 16,794,043 | +0.2% | +0.06% (now 34%) | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 124,8930 | $8.89 | $1.11M | 16,763,043 | +0.8% | +0.26% (now 34%) | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 15,4140 | $8.99 | $138.6K | 16,638,150 | +<0.1% | +0.03% (now 34%) | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 391,0190 | $8.57 | $3.35M | 16,622,736 | +2% | +0.80% (now 34%) | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 548,5800 | $7.91 | $4.34M | 16,231,717 | +3% | +1.1% (now 33%) | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 1030 | $7.00 | $721 | 15,683,137 | +<0.1% | +<0.01% (now 32%) | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 479,0390 | $6.91 | $3.31M | 15,683,034 | +3% | +0.98% (now 32%) | filing |
| 2026-05-28 | GC Corp. +1 more | 10% owner | P | ▲ buy | 347,2220 | $11.52 | $4.00M | 1,607,734 | +28% | +0.71% (now 3.3%) | filing |
| 2026-05-28 | GC Corp. +1 more | 10% owner | P | ▲ buy | 1,085,0690 | $11.52 | $12.50M | 4,391,969 | +33% | +2.2% (now 9.0%) | filing |
| 2026-05-19 | Raymon Heather | Officer (SVP, Research and Development) | S | ▼ sell | 3,0950 | $9.01 | $27.9K | 148,228 | −2% | −<0.01% (now 0.30%) | filing |
| 2026-05-19 | Horan Christopher | Officer (Chief Tech Operations Officer) | S | ▼ sell | 7,0020 | $9.01 | $63.1K | 293,450 | −2% | −0.01% (now 0.60%) | filing |
| 2026-05-19 | Bush Jennifer | Officer (COO, CLO, Compliance Officer) | S | ▼ sell | 8,7900 | $9.01 | $79.2K | 337,920 | −3% | −0.02% (now 0.69%) | filing |
| 2026-05-19 | Banerjee Subhashis | Officer (Chief Medical Officer) | S | ▼ sell | 7,0370 | $9.01 | $63.4K | 144,963 | −5% | −0.01% (now 0.30%) | filing |
| 2026-05-19 | Aslan Fred | Director, Officer (Chief Executive Officer) | S | ▼ sell | 27,1160 | $9.01 | $244.3K | 1,535,082 | −2% | −0.06% (now 3.1%) | filing |
| 2026-05-19 | Miralles Gines Diego | Officer (President & Head of R&D) | A | ▲ buy | 232,500→ 232,500 Common Stock | — | — | 232,500 | — | — | filing |
| 2026-05-19 | Miralles Gines Diego | Officer (President & Head of R&D) | A | ▲ buy | 77,5000 | — | — | 77,500 | new | +0.16% (now 0.16%) | filing |
| 2026-05-13 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 2,170,138→ 2,170,138 Common Stock | $11.52 | $25.00M | 2,170,138 | — | — | filing |
| 2026-05-13 | RA CAPITAL MANAGEMENT, L.P. +5 more | Director, 10% owner, Director | P | ▲ buy | 6,510,4160 | $11.52 | $75.00M | 15,203,995 | +75% | +13% (now 31%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.